Change in Proteinuria After Adding Aldosterone Blockers to ACE Inhibitors or Angiotensin Receptor Blockers in CKD: A Systematic Review

2004, K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease, Am J Kidney Dis, 43, S1 Lewis, 1993, The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy, N Engl J Med, 329, 1456, 10.1056/NEJM199311113292004 Lewis, 2001, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N Engl J Med, 345, 851, 10.1056/NEJMoa011303 Nakao, 2003, Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial, Lancet, 361, 117, 10.1016/S0140-6736(03)12229-5 MacKinnon, 2006, Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: A systematic review of the efficacy and safety data, Am J Kidney Dis, 48, 8, 10.1053/j.ajkd.2006.04.077 Lysaght, 2002, Maintenance dialysis population dynamics: Current trends and long-term implications, J Am Soc Nephrol, 13, S37, 10.1681/ASN.V13suppl_1s37 Coresh, 2003, Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey, Am J Kidney Dis, 41, 1, 10.1053/ajkd.2003.50007 Staessen, 1981, Rise in plasma concentration of aldosterone during long-term angiotensin II suppression, J Endocrinol, 91, 457, 10.1677/joe.0.0910457 Biollaz, 1982, Antihypertensive therapy with MK 421: Angiotensin II–renin relationships to evaluate efficacy of converting enzyme blockade, J Cardiovasc Pharmacol, 4, 966, 10.1097/00005344-198211000-00014 Lee, 1999, Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: A longitudinal study, Eur J Heart Fail, 1, 401, 10.1016/S1388-9842(99)00046-X McKelvie, 1999, Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study, Circulation, 100, 1056, 10.1161/01.CIR.100.10.1056 Cicoira, 2001, Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype, J Am Coll Cardiol, 37, 1808, 10.1016/S0735-1097(01)01237-2 Schjoedt, 2004, Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate, Diabetologia, 47, 1936, 10.1007/s00125-004-1542-0 Rocha, 2000, Aldosterone: A mediator of myocardial necrosis and renal arteriopathy, Endocrinology, 141, 3871, 10.1210/en.141.10.3871 Hollenberg, 2004, Aldosterone in the development and progression of renal injury, Kidney Int, 66, 1, 10.1111/j.1523-1755.2004.00701.x Rocha, 1999, Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats, Hypertension, 33, 232, 10.1161/01.HYP.33.1.232 Greene, 1996, Role of aldosterone in the remnant kidney model in the rat, J Clin Invest, 98, 1063, 10.1172/JCI118867 Conn, 1964, Clinical characteristics of primary aldosteronism from an analysis of 145 cases, Am J Surg, 107, 159, 10.1016/0002-9610(64)90252-1 Jadad, 1996, Assessing the quality of reports of randomized clinical trials: Is blinding necessary?, Control Clin Trials, 17, 1, 10.1016/0197-2456(95)00134-4 Chrysostomou, 2001, Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease, N Engl J Med, 345, 925, 10.1056/NEJM200109203451215 Epstein, 2002, Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria, Am J Hypertens, 15, 24A, 10.1016/S0895-7061(02)02333-6 White, 2003, Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension, Hypertension, 41, 1021, 10.1161/01.HYP.0000067463.13172.EA Flack, 2003, Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients, J Am Coll Cardiol, 41, 1148, 10.1016/S0735-1097(03)00054-8 Furumatsu, 2003, Antiproteinuric effect of triple blockade with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker, and spironolactone, J Am Soc Nephrol, 14, 762A Nowicki, 2003, Nephroprotective effect of combined converting enzyme and aldosterone blockade in hypertensive patients with target organ damage is blood pressure-dependent, J Am Soc Nephrol, 14, 21A Shiigai, 2003, Effect of spironolactone added to angiotensin receptor blocker in renal failure patients, J Am Soc Nephrol, 1, 763A Sato, 2003, Effectiveness of aldosterone blockade in patients with diabetic nephropathy, Hypertension, 41, 64, 10.1161/01.HYP.0000044937.95080.E9 Pitt, 2003, Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-left ventricular hypertrophy study, Circulation, 108, 1831, 10.1161/01.CIR.0000091405.00772.6E Williams, 2004, Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension, Am J Cardiol, 93, 990, 10.1016/j.amjcard.2004.01.007 Rachmani, 2004, The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: A randomized controlled study, Diabet Med, 21, 471, 10.1111/j.1464-5491.2004.01194.x Nitta K, Uchida K, Nihei H: Spironolactone and angiotensin receptor blocker in nondiabetic renal diseases. Am J Med 117:444-445, 200 Furumatsu, 2004, Antiproteinuric effect of triple blockade with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker, and spironolactone: One year follow up, J Am Soc Nephrol, 15, 58A Bianchi, 2005, Antagonists of aldosterone and proteinuria in patients with CKD: An uncontrolled pilot study, Am J Kidney Dis, 46, 45, 10.1053/j.ajkd.2005.03.007 Sato, 2005, Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease, Am J Hypertens, 18, 44, 10.1016/j.amjhyper.2004.06.029 Schjoedt, 2005, Beneficial impact of spironolactone in diabetic nephropathy, Kidney Int, 68, 2829, 10.1111/j.1523-1755.2005.00756.x Rossing, 2005, Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study, Diabetes Care, 28, 2106, 10.2337/diacare.28.9.2106 Schjoedt, 2005, Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy, J Am Soc Nephrol, 16, 57A van den Meiracker, 2006, Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function, J Hypertens, 24, 2285, 10.1097/01.hjh.0000249708.44016.5c Bianchi, 2006, Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease, Kidney Int, 70, 2116, 10.1038/sj.ki.5001854 Schjoedt, 2006, Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy, Kidney Int, 70, 536, 10.1038/sj.ki.5001580 Chrysostomou, 2006, Clin J Am Soc Nephrol, 1, 256, 10.2215/CJN.01040905 Epstein, 2006, Selective aldosterone blockade with eplerenone reduces proteinuria in patients with type 2 diabetes, Clin J Am Soc Nephrol, 1, 940, 10.2215/CJN.00240106 Takebayashi, 2006, Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy, J Clin Endocrinol Metab, 91, 2214, 10.1210/jc.2005-1718 Schulz, 1995, Empirical evidence of bias, JAMA, 273, 408, 10.1001/jama.273.5.408 Moher, 1998, Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?, Lancet, 352, 609, 10.1016/S0140-6736(98)01085-X Smith, 1994, Who benefits from medical interventions?, BMJ, 308, 72, 10.1136/bmj.308.6921.72 Glasziou, 1995, An evidence based approach to individualising treatment, BMJ, 311, 1356, 10.1136/bmj.311.7016.1356 Pitt, 1995, “Escape” of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy, Cardiovasc Drugs Ther, 9, 145, 10.1007/BF00877755 Fullerton, 1994, Aldosterone and cardiac fibrosis: In vitro studies, Cardiovasc Res, 28, 1863, 10.1093/cvr/28.12.1863 Pitt, 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure, N Engl J Med, 341, 709, 10.1056/NEJM199909023411001 Pitt, 2003, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction, N Engl J Med, 348, 1309, 10.1056/NEJMoa030207 Nishiyama, 2006, Molecular mechanisms and therapeutic strategies of chronic renal injury: Renoprotective effects of aldosterone blockade, J Pharmacol Sci, 100, 9, 10.1254/jphs.FMJ05003X3 Zhou, 2004, Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model, Am J Nephrol, 24, 242, 10.1159/000077396 Asai, 2004, Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis, Hypertens Res, 27, 971, 10.1291/hypres.27.971 Nagase, 2006, Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker, Hypertension, 47, 1084, 10.1161/01.HYP.0000222003.28517.99 Struthers, 1996, Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure, J Card Fail, 2, 47, 10.1016/S1071-9164(96)80009-1 Sato, 2001, Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy, J Int Med Res, 29, 13, 10.1177/147323000102900103 Lakkis, 2003, RAAS escape: A real clinical entity that may be important in the progression of cardiovascular and renal disease, Curr Hypertens Rep, 5, 408, 10.1007/s11906-003-0087-9 Horita, 2006, Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy, Nephrology (Carlton), 11, 462, 10.1111/j.1440-1797.2006.00665.x Juurlink, 2004, Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study, N Engl J Med, 351, 543, 10.1056/NEJMoa040135 Prakash, 2005, “Aldosterone escape” or refractory hyperaldosteronism?, MedGenMed, 7, 25